These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26975539)

  • 21. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
    Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
    J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.
    Chen WJ; Rijzewijk LJ; van der Meer RW; Heymans MW; van Duinkerken E; Lubberink M; Lammertsma AA; Lamb HJ; de Roos A; Romijn JA; Smit JW; Bax JJ; Bjerre M; Frystyk J; Flyvbjerg A; Diamant M
    Cardiovasc Diabetol; 2011 Jul; 10():67. PubMed ID: 21771299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Value of Osteoprotegerin for Detecting Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients in Correlation with Extent of Calcification Detected by Multidetector Computed Tomography.
    Ahmed S; Sobh R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):845-851. PubMed ID: 30747085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.
    Erol M; Bostan Gayret O; Tekin Nacaroglu H; Yigit O; Zengi O; Salih Akkurt M; Tasdemir M
    Iran Red Crescent Med J; 2016 Nov; 18(11):e41873. PubMed ID: 28203453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity.
    Jørgensen GM; Vind B; Nybo M; Rasmussen LM; Højlund K
    Eur J Endocrinol; 2009 Jul; 161(1):95-101. PubMed ID: 19380455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.
    Poulsen MK; Nybo M; Dahl J; Hosbond S; Poulsen TS; Johansen A; Høilund-Carlsen PF; Beck-Nielsen H; Rasmussen LM; Henriksen JE
    Cardiovasc Diabetol; 2011 Aug; 10():76. PubMed ID: 21838881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?
    Shabani P; Naeimi Khaledi H; Beigy M; Emamgholipour S; Parvaz E; Poustchi H; Doosti M
    PLoS One; 2015; 10(3):e0118650. PubMed ID: 25767880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.
    Mantovani A; Sani E; Fassio A; Colecchia A; Viapiana O; Gatti D; Idolazzi L; Rossini M; Salvagno G; Lippi G; Zoppini G; Byrne CD; Bonora E; Targher G
    Diabetes Metab; 2019 Sep; 45(4):347-355. PubMed ID: 30315891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis.
    Kim J; Song TJ; Yang SH; Lee OH; Nam HS; Kim YD; Kim EH; Lee HS; Nam CM; Heo JH
    Clin Biochem; 2013 Aug; 46(12):1036-1040. PubMed ID: 23726804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes.
    Yaturu S; Rains J; Jain SK
    Cytokine; 2008 Oct; 44(1):168-71. PubMed ID: 18789716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.
    Giaginis C; Papadopouli A; Zira A; Katsargyris A; Klonaris C; Theocharis S
    Med Sci Monit; 2012 Oct; 18(10):CR597-604. PubMed ID: 23018352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes.
    El-Ashmawy HM; Ahmed AM
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):859-864. PubMed ID: 30601337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Wang C; He M; Peng J; Li S; Long M; Chen W; Liu D; Yang G; Zhang L
    Cytokine; 2020 Jan; 125():154837. PubMed ID: 31514105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma selenium levels and nonalcoholic fatty liver disease in Chinese adults: a cross-sectional analysis.
    Yang Z; Yan C; Liu G; Niu Y; Zhang W; Lu S; Li X; Zhang H; Ning G; Fan J; Qin L; Su Q
    Sci Rep; 2016 Nov; 6():37288. PubMed ID: 27853246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma Alkylresorcinol Metabolite, a Biomarker for Whole-Grain Intake, Is Inversely Associated with Risk of Nonalcoholic Fatty Liver Disease in a Case-Control Study of Chinese Adults.
    Sun T; Deng Y; Geng X; Fang Q; Li X; Chen L; Zhan M; Li D; Zhu K; Li H; Liu L
    J Nutr; 2022 Apr; 152(4):1052-1058. PubMed ID: 35091747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.
    Secchiero P; Corallini F; Pandolfi A; Consoli A; Candido R; Fabris B; Celeghini C; Capitani S; Zauli G
    Am J Pathol; 2006 Dec; 169(6):2236-44. PubMed ID: 17148684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes.
    Blázquez-Medela AM; García-Ortiz L; Gómez-Marcos MA; Recio-Rodriguez JI; Sánchez-Rodríguez A; López-Novoa JM; Martínez-Salgado C
    Eur J Clin Invest; 2012 May; 42(5):548-56. PubMed ID: 22050177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.
    Tavintharan S; Pek LT; Liu JJ; Ng XW; Yeoh LY; Su Chi L; Chee Fang S
    Diab Vasc Dis Res; 2014 Sep; 11(5):359-62. PubMed ID: 25005034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.